Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 12, 2012, Pages

  Nasu, Tatsuyo ^a   Kinomura, Masaru ^a   Tanabe, Katsuyuki ^a   Yamasaki, Hiroko ^a   le Htay, Su ^a   Saito, Daisuke ^a   Hinamoto, Norikazu ^a   Watatani, Hiroyuki ^a   Ujike, Haruyo ^a   Suzuki, Yoshinori ^b   Sugaya, Takeshi ^c   Sugiyama, Hitoshi ^a   Sakai, Yoshiki ^d   Matsumoto, Kunio ^b   Maeshima, Yohei ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Strategic and Regulatory Affairs Consulting Department   (Japan)

^d ONO PHARMACEUTICAL CO   (Japan)

Author keywords

FSP 1; HGF; Prostacyclin; TGF 1; Unilateral ureteral obstruction

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; POLYGLACTIN; PROSTACYCLIN RECEPTOR; PROTEIN ZO1; SCATTER FACTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; URETER OBSTRUCTION;

EID: 84862591610     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00538.2011     Document Type: Article

References (64)

1. Bascands JL, Schanstra JP. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 68: 925-937, 2005.
2. Dai C, Saleem MA, Holzman LB, Mathieson P, Liu Y. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int 77: 962-973.
3. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996.
4. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 5: 319-328, 2009.
5. Hashimoto N, Maeshima Y, Satoh M, Odawara M, Sugiyama H, Kashihara N, Matsubara H, Yamasaki Y, Makino H. Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 286: F516-F525, 2004.
6. Hayashi K, Nagamatsu T, Oka T, Suzuki Y. Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J Pharmacol 73: 73-82, 1997.
7. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97, 2010.
8. Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, Takazawa Y, Sugiyama H, Yamasaki Y, Agata N, Makino H. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 55: 1232-1242, 2006.
9. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H. Anti-angiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54: 2891-2903, 2005.
10. Imawaka H, Sugiyama Y. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. J Pharmacol Exp Ther 284: 949-957, 1998.
11. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K, Yamashiro Y, Ogawa H, Nakao A. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 66: 597-604, 2004.
12. Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, Nishida T, Takigawa M, Ueno M, Nakamura T, Suzuki H. Hepatocyte growth factor counteracts transforming growth factor-p1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 17: 268-270, 2003.
13. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002.
14. Iwata H, Nakamura K, Sumi M, Ninomiya M, Sakai Y, Hirata Y, Akaike M, Igarashi T, Takamoto S, Nagai R, Sata M. Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci 85: 255-261, 2009.
15. Kataoka M, Nagaya N, Satoh T, Itoh T, Murakami S, Iwase T, Miyahara Y, Kyotani S, Sakai Y, Kangawa K, Ogawa S. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 172: 1575-1580, 2005.
16. Kimura A, Ishida Y, Wada T, Hisaoka T, Morikawa Y, Sugaya T, Mukaida N, Kondo T. The absence of interleukin-6 enhanced arsenite-induced renal injury by promoting autophagy of tubular epithelial cells with aberrant extracellular signal-regulated kinase activation. Am J Pathol 176: 40-50, 2010.
17. Komhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM. Localization of the prostacyclin receptor in human kidney. Kidney Int 54: 1899-1908, 1998.
18. Kondo K, Machii K, Narita M, Kawamoto A, Yamasaki S, Hamanaka N. ONO-AP-500-2: A Nonprostanoid Prostaglandin I Mimetic with Inhibitory Activity Against Thromboxane Sybthase. New York: Raven, 2005, p. 401-403.
19. Kushiro M, Shikata K, Sugimoto H, Shikata Y, Miyatake N, Wada J, Miyasaka M, Makino H. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int 53: 1314-1320, 1998.
20. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 14: 1535-1548, 2003.
21. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor-fj1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 11: 851-857, 1997.
22. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 287: F7-F16, 2004.
23. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 21: 212-222, 2010.
24. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006.
25. Maeshima Y, Kashihara N, Sugiyama H, Makino H, Ota Z. Antisense oligonucleotides to proliferating cell nuclear antigen and Ki- 67 inhibit human mesangial cell proliferation. J Am Soc Nephrol 7: 2219-2229, 1996.
26. Maeshima Y, Kashihara N, Yasuda T, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Watanabe Y, Kanwar YS, Makino H. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest 101: 2589-2597, 1998.
27. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295: 140-143, 2002.
28. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59: 2023-2038, 2001.
29. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y, Okamoto M, Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101: 1827-1834, 1998.
30. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59: 1304-1314, 2001.
31. Mizuno S, Nakamura T. Suppressions of chronic glomerular injuries and TGF-fj1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 286: F134-F143, 2004.
32. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
33. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 300: 1142-1147, 1979.
34. Murakami S, Nagaya N, Itoh T, Kataoka M, Iwase T, Horio T, Miyahara Y, Sakai Y, Kangawa K, Kimura H. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 290: L59-L65, 2006.
35. Nagamatsu T, Kojima J, Ito M, Kondo N, Suzuki Y. Antinephritic effects of PGE1 and thiaprostaglandin E1, TEI-5178 and TEI-6122 on crescentic-type anti-GBM nephritis in rats. Jpn J Pharmacol 51: 521-530, 1989.
36. Nagao T, Nagamatsu T, Suzuki Y. Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats. Jpn J Pharmacol 68: 137-144, 1995.
37. Nakamura K, Sata M, Iwata H, Sakai Y, Hirata Y, Kugiyama K, Nagai R. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (Lond) 112: 607-616, 2007.
38. Nasrallah R, Landry A, Scholey JW, Hebert RL. Characterization of the PGI2/IP system in cultured rat mesangial cells. Prostaglandins Leukot Essent Fatty Acids 70: 455-464, 2004.
39. Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, Sonoda H, Sato Y, Makino H. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58: 2365-2375, 2009.
40. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1-17, 1992.
41. Obata H, Sakai Y, Ohnishi S, Takeshita S, Mori H, Kodama M, Kangawa K, Aizawa Y, Nagaya N. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 177: 195-201, 2008.
42. Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 125: 1315-1324, 1998.
43. Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A, Narumiya S. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 116: 2828-2837, 1995.
44. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition. Kidney Int 80: 41-50, 2011.
45. Rinder CA, Halushka PV, Sens MA, Ploth DW. Thromboxane A2 receptor blockade improves renal function and histopathology in the post-obstructive kidney. Kidney Int 45: 185-192, 1994.
46. Rudd JA, Qian Y, Tsui KK, Jones RL. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br J Pharmacol 129: 782-790, 2000.
47. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K, Sugiyama H, Sonoda H, Sato Y, Makino H. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 300: F873-F886, 2011.
48. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-fj1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486-1494, 2003.
49. Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 59: 1092-1100, 2010.
50. Satoh M, Kashihara N, Yamasaki Y, Maruyama K, Okamoto K, Maeshima Y, Sugiyama H, Sugaya T, Murakami K, Makino H. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 12: 317-325, 2001.
51. Schreiner GF, Harris KP, Purkerson ML, Klahr S. Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int 34: 487-493, 1988.
52. Sebekova K, Eifert T, Klassen A, Heidland A, Amann K. Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 56: 968-974, 2007.
53. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130: 393-405, 1995.
54. Sunami R, Sugiyama H, Wang DH, Kobayashi M, Maeshima Y, Yamasaki Y, Masuoka N, Ogawa N, Kira S, Makino H. Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction. Am J Physiol Renal Physiol 286: F1030-F1038, 2004.
55. Takenaka M, Machida N, Ida N, Satoh N, Kurumatani H, Yamane Y. Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model. Prostaglandins Leukot Essent Fatty Acids 80: 263-267, 2009.
56. Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K, Kinomura M, Sugiyama H, Makino H. Endostatin pep-tide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 71: 227-238, 2007.
57. Tashiro K, Hagiya M, Nishizawa T, Seki T, Shimonishi M, Shimizu S, Nakamura T. Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci USA 87: 3200-3204, 1990.
58. Watanabe M, Nakashima H, Mochizuki S, Abe Y, Ishimura A, Ito K, Fukushima T, Miyake K, Ogahara S, Saito T. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I (2) analog, beraprost sodium. Am J Nephrol 30: 1-11, 2009.
59. Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL, Corda S, Lavielle G, Verbeuren TJ, Zuccollo A, Cohen RA. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55: 110-119, 2006.
60. Yamasaki H, Maeshima Y, Nasu T, Saito D, Tanabe K, Hirokoshi-Kawahara K, Sugiyama H, Sakai Y, Makino H. Intermittent administration of a sustained-release prostacyclin analog ONO-1301 ameliorates renal alterations in a rat type 1 diabetes model. Prostaglandins Leukot Essent Fatty Acids 84: 99-107, 2011.
61. Yamashita T, Shikata K, Matsuda M, Okada S, Ogawa D, Sugimoto H, Wada J, Makino H. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes Res Clin Pract 57: 149-161, 2002.
62. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13: 96-107, 2002.
63. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106: 2397-2403, 2002.
64. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968, 2003.